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Abstract
Multiple evidences indicate that inflammation is an event occurring prior to infection in patients
with cystic fibrosis. The self-perpetuating inflammatory cycle may play a pathogenic part in this
disease. The role of the NF-κB pathway in enhanced production of inflammatory mediators is well
documented. The pathophysiologic mechanisms through which the intrinsic inflammatory response
develops remain unclear. The unfolded mutated protein cystic fibrosis transmembrane
conductance regulator (CFTRΔF508), accounting for this pathology, is retained in the endoplasmic
reticulum (ER), induces a stress, and modifies calcium homeostasis. Furthermore, CFTR is
implicated in the transport of glutathione, the major antioxidant element in cells. CFTR mutations
can alter redox homeostasis and induce an oxidative stress. The disturbance of the redox balance
may evoke NF-κB activation and, in addition, promote apoptosis. In this review, we examine the
hypotheses of the integrated pathogenic processes leading to the intrinsic inflammatory response
in cystic fibrosis.
Introduction
Cystic Fibrosis (CF) is the most common inherited auto-
somal recessive and lethal disease in caucasian population
[1]. It is due to mutations in the product of the gene
encoding the cystic fibrosis transmembrane conductance
regulator (CFTR) [2]. This ATP-binding cassette (ABC)
transporter is a membrane glycoprotein that functions not
only as a cyclic AMP-regulated chloride channel in epithe-
lial cells but also, as a reduced glutathione transporter
[3,4]. Moreover, CFTR can regulate other channels such as
the outwardly rectifying Cl- channels (ORCC), epithelial
Na+ channels (ENaC), renal outer medullary K+ channels
(ROMK) or other inwardly rectifying K+ channels [5]. It is
expressed in various organs such as lung, pancreas, liver,
gastrointestinal tract, and sweat glands [1].
More than 1,500 mutations of CFTR have been identified
[6]. Mutations affect localization of CFTR at the apical
plasma membrane and could interfere with its function
and regulation. The most common mutation, deletion of
phenylalanine at position 508 (CFTRΔF508), results in a
misfolded protein that is retained in the endoplasmic
reticulum (ER) [7]. The lack of functional CFTR at the
plasma membrane correlates with impaired ionic balance
and modification of cellular homeostasis. This pathologi-
cal aspect is well documented and is characterized by thick
secretions [8-11]. Thus, viscous and hyper-concentrated
pancreatic secretions obstruct pancreatic ducts in CF
patients accounting for the destruction of pancreas epithe-
lium, which could promote inflammation [12,13]. Con-
cerning the respiratory system, airway obstruction
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resulting from the thick mucus and reduced clearance of
inhaled particles, including bacteria, promotes persistent
infection and chronic inflammation [14] that are the
major causes of death [15]. However, even in the absence
of bacterial or viral pathogens, exacerbated inflammation
has been reported in the respiratory tract of CF infants
[16-18]. Hence, the origin of inflammation in CF has
been a matter of debate and, recent data suggest that the
retention of the misfolded protein could play a key role in
the development and maintenance of the inflammatory
response.
In the present review, we examine hypotheses of the coor-
dinated and integrated pathophysiologic processes associ-
ated with CFTR defect retention in the ER that could lead
to intrinsic inflammatory and apoptotic responses.
Defects in CFTR and inflammatory responses
Although several studies have shown that CF and normal
cells did not differ in both cytokine profile secretion and
NF-κB activation [19,20], a large amount of data show
that CF cells appear to produce excessive quantity of pro-
inflammatory cytokines such as interleukin (IL)-8, IL-6 or
RANTES [21-23]. Concretely, airway tract, and more par-
ticularly lungs, of CF patients present a high density of
acute inflammatory cells, chiefly infiltrated neutrophils
and macrophages, even in the absence of bacteria [24,25].
Moreover, airway infiltrated neutrophils are associated
with high levels of pro-inflammatory mediators and
cytokines like IL-8. In addition to a specific cytokine secre-
tion profile, it has been observed that neutrophils from
patients with CF show phenotype alteration(s) associated
with functional and signaling changes, such as increased
lipid raft assembly and increased levels of the cytoskele-
ton-associated phospho-Syk kinase [26]. Besides, blood
and airway neutrophils in CF produce high basal levels of
IL-8 that increase after lipopolysaccharide (LPS) treat-
ment, suggesting an exaggerated basal pro-inflammatory
cytokine secretion that could further augment under
inflammatory conditions [27,28] (Figure 1). Co-cultures
of polymorphonuclear (PMN) cells from CF and non-CF
airways with CFTR-mutated and CFTR-corrected epithelial
cell lines, respectively, have shown that PMN from CF air-
ways and CFTR-mutated epithelial cell lines are responsi-
ble for pro-inflammatory cytokine production [29].
Furthermore, CFTR correction in epithelial cells did not
allow return to levels of cytokine expression towards lev-
els of normal cells, revealing an activated inflammatory
intrinsic pathway in CF epithelial cells. In addition, a dis-
turbance of the balance between inflammatory versus
anti-inflammatory mediator production has also been
described in CF cells [30,31]. Thus, the release of IL-10,
the anti-inflammatory cytokine known to reduce IκB deg-
radation (an inhibitor of NF-κB) [32], is reduced [33],
whereas pro-inflammatory cytokines are over-expressed
in association with an increase of both NF-κB and AP-1
activities that are under the control of IκB kinase and ERK
signaling pathway (Figure 1). Moreover, pro-inflamma-
tory cytokines, like IL-1β and FGF, promote activation of
NF-κB and AP-1, participating in the perpetuation of the
vicious cycle of inflammation [34]. Indeed, implication of
NF-κB in inflammatory status in CF is well documented;
AP-1 also appears to play an important role in inflamma-
tion [34,35]. However, the beneficial effect of miglustat
[36], without affecting NF-κB and AP-1 status, is in favor
of the implication of other transcription factors, notably
ATF-6 implicated in the unfolded protein response (UPR)
Representation of the noxious inflammatory cycle in CF cell:  Pro-inflammatory cytokines and external stimuli, such as  pathogens, activate ERK pathway and promote dissociation  of NF-κB/IκB complexe leading to NF-κB activation Figure 1
Representation of the noxious inflammatory cycle in 
CF cell: Pro-inflammatory cytokines and external 
stimuli, such as pathogens, activate ERK pathway and 
promote dissociation of NF-κB/IκB complexe leading 
to NF-κB activation. Retention of CFTRΔF508 in endo-
plasmic reticulum (ER), excessive production of reactive oxy-
gen species (ROS) by mitochondria and alteration of 
ceramide levels leads to NF-κB activation, resulting in inflam-
mation.Respiratory Research 2009, 10:23 http://respiratory-research.com/content/10/1/23
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(see below) and Nrf-2 implicated in defense against oxi-
dative stress [37].
In agreement with results obtained in cells cultured
directly from uninfected CF tissues, Weber et al., [38] have
found that defects of CFTR, in function of localization,
contribute to endogenous activation of NF-κB, and conse-
quently to the exaggerated production of the pro-inflam-
matory cytokine IL-8, even in the absence of bacteria. It
should be noted that the link between CFTR defects and
NF-κB activation must be strengthened during bacterial
infection as described for Pseudomonas aeruginosa [39-41].
In addition, after LPS treatment a pro-inflammatory envi-
ronment induces excessive NF-κB activation in CF macro-
phages, as above described for neutrophils [27,28], that is
associated with a high production of pro-inflammatory
cytokines [42,43]. This excessive production of cytokines
results from CFTR dysfunction because the effect of LPS
was also observed in healthy heterozygotes [44], suggest-
ing that a single allelic CFTR mutation is sufficient for
increase of the inflammatory response.
CFTR and apoptosis
Contradictory data on the sensitivity of CF cells to apop-
tosis have been reported. Whereas intestinal epithelial CF
cells show a higher fragmentation of DNA [45], suggesting
an elevated susceptibility to programmed cell death, respi-
ratory epithelial CF cells undergo delayed Pseudomonas
aeruginosa-induced apoptosis [46]. Also, neutrophils from
CF patients present a prolonged survival when compared
to normal counterparts [47]. In agreement with these
observations, an over-expression of the antiapoptotic pro-
tein Bcl-2 has been evidenced in CF patients [48]. By con-
trast, we have recently demonstrated [22] that CF
epithelial cells from pancreas or trachea are more sensitive
to apoptosis compared to normal cells. In addition, con-
ditioned medium from apoptotic CF cells promotes apop-
tosis in normal cells, indicating that the release of
mediators of inflammation during apoptosis is in turn
able to evoke apoptosis [22]. Furthermore, macrophages
from CF patients produce more TNF-α than their counter-
parts [49], and the increased secretion of Fas and FasLig-
and by CF epithelial cells [50], consolidate these
observations. Increased susceptibility to apoptosis in epi-
thelial cells and failed apoptosis in neutrophils would
contribute to the self-perpetuating inflammatory cycle in
CF. Independently of the susceptibility to apoptosis of CF
cells, it has been shown that clearance of apoptotic cells is
defective and that accumulation of such cells could con-
tribute to ongoing inflammation in CF patients [51].
CFTR and endoplasmic reticulum
ER has several specialized functions: (i) it is implicated in
maturation, folding and transport of newly synthesized
proteins; (ii) it is the site of biosynthesis for many lipids;
and (iii) it acts as a calcium reservoir [52]. The ER contains
intraluminal machinery composed of a large number of
chaperone proteins implicated in the "quality control sys-
tem" [53]. Proteins translocated into the ER lumen inter-
act with chaperone proteins to acquire their conformation
and then they are transported to the cell membrane or are
secreted. Acquisition of conformation and formation of
disulfide bonds needs resident chaperone proteins, high
levels of calcium and an oxidative environment specific to
the ER [54]. Accumulation of misfolded proteins, altera-
tions of calcium homeostasis, inflammation or hypoxia,
causing perturbations in environment, lead to disrupted
ER function, also referred as to "ER stress" [55]. The most
common mutation of CFTR produces an incorrectly
folded protein, CFTRΔF508, which is present within the
ER, and accumulates in the ER-Golgi intermediate com-
partment [56] causing an ER stress. In addition, in ER
CFTRΔF508 interacts with calcium-dependent chaper-
ones, modifying calcium homeostasis [57] and generating
further stress [58].
Under ER stress conditions, three different pathways are
activated in order to reduce the synthesis of new proteins
and to increase degradation of uncorrected proteins (Fig-
ure 2): (i) the UPR that leads to a reduction of protein syn-
thesis and transcription of chaperone target genes, (ii) the
ER-associated degradation (ERAD) in order to eliminate
misfolded proteins by proteasome, and (iii) in case these
responses are unsuccessful, the ER-overload response
(EOR) leading to apoptosis [59]. ER stress generated by
misfolded CFTRΔF508 protein activates the UPR and the
over-expression of several ER resident chaperones such as
Grp78 [60], resulting in decreased CFTR expression
[61,62]. In addition, in CFTRΔF508 cells, Kerbiriou et al.
[60] have described an increase of ATF6 form, an initiator
of UPR that is accompanied with its translocation into the
nuclei. Using cells expressing different mutations of CFTR,
Weber et al. [38] have demonstrated that accumulation of
CFTR in the ER contributes to the endogenous activation
of NF-κB. Also, Verhaege et al. [34] have shown that acti-
vation of NF-κB and AP-1 transcription factors are
dependent on the ER sequestration of the misfolded
CFTRΔF508 protein.
ERAD, a component of a coordinated cellular response to
ER stress, can be activated and induces protein removal
from the ER and degradation in the cytosol, via the ubiq-
uitin-proteasome system. Thus, after being selected by
quality control system, the ubiquitin proteasome system
interacts with unfolded ER proteins and cofactors that per-
mit their translocation from ER to cytosol, where they are
polyubiquitynated by ubiquitin ligase system, and then
degraded by cytosolic proteasome system. Among the
misfolded proteins processed by ERAD and the ubiquitin
proteasome system, CFTRΔF508 is detected in the cytosolRespiratory Research 2009, 10:23 http://respiratory-research.com/content/10/1/23
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and within the ER membrane by the ERAD components,
and finally, it can be degraded by proteasome [63,64]. In
particular, in CF bronchial epithelial cells from
CFTRΔF508 homozygous patients, the p97/valosin-con-
taining protein (VCP), which is an integral component of
ERAD, is over-expressed compared with non-CF bronchial
epithelial cells. Moreover, inhibition of VCP induces the
rescue of CFTRΔF508 protein to the plasma membrane
that is associated with the diminution of NF-κB activation
and the reduction of IL-8 secretion. The fact that the ERAD
system, or at least some of the components, is up-regu-
lated in CF could explain, in part, the exaggerated NF-κB
activation in cells presenting CFTR defects [65].
When UPR and ERAD signaling pathways are not suffi-
cient to restore normal cell parameters, cells could activate
EOR in order to induce apoptosis [59]. It has been
described that, independently of UPR activation, the accu-
mulation of unfolded proteins in the ER membranes pro-
vides an NF-κB-activating stimulus [66]. Several
messengers have been proposed as signals from the ER for
NF-κB activation, such as the efflux of calcium or the reac-
tive oxygen species (ROS) [67]. It is possible that the con-
stitutive NF-κB activation observed in CF cells could be
the consequence of EOR in response to CFTR accumula-
tion in the ER membranes as described by Knorre and col-
leagues [68]. Exaggerated NF-κB activation, apoptosis and
pro-inflammatory mediator productions have also been
described in CF pancreatic and tracheal cells [22] suggest-
ing that EOR may be implicated in theses events.
Altogether, prevention of the retention of CFTR in the ER
and its rescue at the plasma membrane may be a key ele-
ment in CF pathogenesis, and CFTRΔF508 correction
based on the activation of different ER-linked systems can
represent new approaches of this disease [69-71].
CFTR and calcium homeostasis
In agreement with the observations that ER plays a major
role in the CF pathology, it has been shown that calcium
homeostasis is altered in cells presenting CFTR mutations.
Antigny et al. [57] have shown that the release of calcium
from ER stores by agonists, such as histamine or ATP, is
increased in CF cells. More important, the rescue of
CFTRΔF508 at the plasma membrane by incubating cells
at low temperature (27°C) restored calcium mobilization
at similar levels than those measured in normal cells.
In CF human airway epithelia, other studies have
described a higher calcium mobilization in response of G
protein-coupled receptors to nucleotides or bradykinin,
suggesting that the apical ER/calcium store compartment
is expanded [72]. However, these authors propose that the
increase in ER volume could be attributable to airway
infection and inflammation rather than the intrinsic CFTR
defects since in the absence of infection or after long term
culturing CF cells, ER expansion is abolished. In addition,
same authors have established a relationship between
inflammation and ER expansion [73]. Indeed, the
increase in IL-8 secretion induced after bradykinin treat-
ment was mediated by an increased calcium mobilization
consecutive to ER expansion. The link between inflamma-
tion and calcium mobilization has been confirmed by the
work from Tabary et al. [74]. Using a model of individual
living airway epithelial cell monitoring, they have shown
Involvement of misfolded CFTRΔF508 in endoplasmic reticu- lum (ER) stress in CF cell: Retention of CFTRΔF508 is associ- ated with an increase of Ca2+ concentration in the lumen of  ER and with the interaction with chaperone proteins Figure 2
Involvement of misfolded CFTRΔF508 in endoplas-
mic reticulum (ER) stress in CF cell: Retention of 
CFTRΔF508 is associated with an increase of Ca2+ 
concentration in the lumen of ER and with the inter-
action with chaperone proteins. This induces activation 
of ERAD in order to degrade misfolded CFTRΔF508 by pro-
teasome. In addition, increase of Grp78 induces activation of 
the UPR via the ATF-6. Whether ERAD and UPR are not suf-
ficient to restore normal cellular parameters, EOR is acti-
vated resulting in apoptosis induction.Respiratory Research 2009, 10:23 http://respiratory-research.com/content/10/1/23
Page 5 of 11
(page number not for citation purposes)
that inflammatory mediators such as IL-1β are able to
induce an increased calcium release, which is accompa-
nied by activation of NF-κB in CF cells. Depletion of cal-
cium stores from ER or inhibition of NF-κB activation
leads to a decrease in calcium responses suggesting that
inflammatory cytokines regulate calcium handling in CF
cells, and in turn, calcium mobilization controls NF-κB
activation contributing to a noxious cycle. In this context,
the most common pathogens in CF, Pseudomonas aerugi-
nosa  and  Staphylococcus aureus, promote an increase of
intracellular calcium concentration in CF cells that lead to
NF-κB activation and proinflammatory cytokine produc-
tion via ERK1/2 and p38 pathways [75].
Other evidences suggest that the excess of calcium seques-
tration in ER may contribute to the abnormal trafficking
of CFTRΔF508. Indeed, it has been demonstrated that the
decrease and the maintenance of low calcium levels in ER,
by using SERCA inhibitors, prevent the interaction
between CFTRΔF508 and chaperones and thus this
restores CFTRΔF508 at the plasma membrane [76,77].
In addition to ER expansion, mitochondria from CF lym-
phocytes display calcium accumulation [78], that could
be explained by the higher activities of several enzymes
involved in the cell energy metabolism such as NADH oxi-
dase, NADH- and succinate-cytochrome c reductases [79].
CFTR and oxidative stress
When the balance between antioxidants and oxidants is
no longer able to prevent the alteration of physiological
functions, oxidative stress takes place. In airways in partic-
ular, ROS, a general term for a number of various and
highly reactive oxygen derived ions or molecules, includ-
ing both radicals and non-radicals, are the main oxidant
species. ROS display beneficial and deleterious effects,
depending of their concentration; an increase occurs
when cells present an imbalance between the production
and the neutralization of free radicals by antioxidant
defense systems. Thus, ROS excess has been described to
promote inflammatory gene transcription [80]. In addi-
tion, the interaction of ROS with nitric oxide (NO), result-
ing in reactive nitrogen species formation, can further
enhance their potential deleterious effects [81,82].
Among the effects due to excessive production of ROS, the
oxidation of macromolecules causes irreversible damage
in molecular targets like proteins, DNA and lipids [83].
CFTR and GSH
Glutathione, an ubiquitous tripeptide, is one of the most
important antioxidant molecules. Glutathione exists in
reduced monomeric (GSH) and oxidized dimeric forms
(GSSG). GSH is found in extracellular fluids, in lung and
in cells at high concentrations of its reduced form. Extra-
cellular GSH neutralizes free radicals produced by neu-
trophils during inflammation [84]. Taking into
consideration that CFTR permits the transport of GSH
between cells and apical extracellular media [85], it is rea-
sonable to imagine that intracellular GSH content may be
altered in CF. In this respect, contradictory data on GSH
content in lung fluid of CF patients have been reported
(for review, see [86]). Indeed, in epithelial lining fluids,
like plasma, the concentration of GSH, but not GSSG, is
reduced compared with normal subjects [25]. The level of
GSH in plasma of CF patients is also reduced suggesting
that GSH deficiency is not limited to the site of inflamma-
tion but is rather systemic [25]. Gao and collaborators
[84] have shown that, in cell lines expressing CFTR muta-
tions or transfected with normal CFTR, GSH efflux is
lower in the former indicating an abnormal transport of
GSH associated with a defective CFTR. Interestingly, it has
been reported that nebulized buffered GSH or the combi-
nation of oral GSH and inhaled buffered GSSG attenuates
CF disease [87,88], suggesting that new approaches
against altered cellular redox status may represent poten-
tial treatments of CF. Not only cellular content of GSH is
altered in CF, low mitochondria GSH levels have also
been described in both lung from CFTR-deficient mice
and human lung epithelial cells lines expressing CFTR
mutations [89]. Because GSH is known to inhibit IκBα
degradation [90,91], low levels of GSH in CF cells may
promote NF-κB activation and participate in the mainte-
nance of inflammation. By contrast, Jungas et al. [92] have
measured an increase of intracellular GSH levels in epithe-
lial cells (HeLa) transfected with CFTRΔF508 compared to
wild-type cells, and this is associated with a defective
apoptosis in CF cells probably due to a slower GSH deple-
tion. In agreement with this work, Day et al. [93] have
shown an increase of GSSG in epithelial lining fluid from
CFTR-deficient mice after Pseudomonas aeruginosa infec-
tion resulting in a reduction of the GSH/GSSG ratio indi-
cating an increased oxidative stress.
CFTR and reactive oxygen species
Elevated markers of oxidative stress, like lipid hydroperox-
idation and protein oxidation, have been measured in
plasma from CF patients and are associated with dimin-
ished concentration of plasma antioxidants [94,95]. Thus,
elevated lipid peroxidation could be associated with pul-
monary dysfunction leading to damage of structural
membranes. An elevation of urine concentration of a
marker of ROS-induced DNA damage, 8-hydroxydeoxy-
guanosine, has also been described in CF patients, sug-
gesting that in CF an increased susceptibility to oxidative-
induced DNA damage may explain the further incidence
of malignancy [96] (Figure 3).
In epithelial lining fluid in lung of CFTR-deficient mice,
Velsor et al. [89] have shown an increase of markers of
oxidative stress related to lipid and DNA oxidation. Fur-Respiratory Research 2009, 10:23 http://respiratory-research.com/content/10/1/23
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thermore, in a CF epithelial cell line, they have reported
high intracellular levels of hydrogen peroxide, reflecting
oxidative stress. Moreover, mitochondrial levels of ROS
(superoxide anion and hydrogen peroxide) are enhanced
in CFTR-deficient cell line [97]. Altogether, these results
indicate that elevated levels of mitochondrial and cellular
ROS are associated with a CFTR-deficient state. The effects
of ROS may be double in CF, on the one hand, it is known
that cellular stress induced by ROS inhibits CFTR matura-
tion, levels and function [58] (Figure 3). On the other
hand, an increase of ROS leads to MAPK signaling path-
way activation [83]. Because this cascade is known to reg-
ulate pro-inflammatory gene expression in CF cells [34], it
is reasonable to hypothesize that ROS are implicated in
the initiation or/and the maintenance of the inflamma-
tory state in CFTR deficiency. In addition, an excessive
production of pro-inflammatory cytokines could increase
ROS production [98] perpetuating the vicious circle of
inflammation in CF (Figure 3).
Defective neutralization of ROS can also elicit oxidative
stress. Three superoxide dismutases (SOD) have been
described in mammals, Cu/Zn-SOD or SOD1, Mn-SOD
or SOD2, and extracellular-SOD or SOD3 (for review see
[99]). These enzymes are implicated in decreasing super-
oxide anion levels that damage cells at excessive concen-
tration [100]. Alterations in the expression or/and activity
of SODs have been described in several pathologies such
as amyotrophic lateral sclerosis for SOD1 [101], cardio-
myopathies for SOD2 [102] and lung diseases for SOD3
[103]. Indeed, SOD3 is highly expressed in lungs and is
associated with decreased recruitment of neutrophils, sug-
gesting an important role in regulating pulmonary inflam-
mation [99]. Although no direct evidence has shown the
involvement of SOD3 in CF, the fact that it is highly
expressed in airways raises the possibility that it may play
a role in CF. In addition, pro-inflammatory cytokines
increase SOD3 expression, in culture and in animal mod-
els of lung injury [104,105].
In agreement with these studies, we have observed a dim-
inution of the expression of three isoforms of SOD, in
pancreatic and tracheal CF cells compared to their respec-
tive controls. In addition, direct measurements of super-
oxide anion production by electronic paramagnetic
resonance correlate with the diminution of SOD expres-
sion suggesting an adaptive response to oxidative stress, in
CF cells (unpublished results).
Taken together, deficiency in antioxidant systems seems
to be associated with all CFTR mutations. Thus, in CF
patients, inadequate antioxidant defenses are associated
with the elevated oxidative stress, which contributes to the
decline of pulmonary function.
CFTR and NO
NO plays a dual role under inflammatory conditions. On
the one hand, NO acts as a bronchodilator molecule, is
able to modulate immune responses, possesses antimicro-
bial activities and acts as an important signaling molecule.
One the other hand, reactions of NO with ROS can origi-
nate intermediate reactive species that have deleterious
properties. Three different isoforms of NO synthase are
expressed in normal lung tissue but only one, iNOS, leads
to production of NO that has antimicrobial properties by
reducing  Pseudomonas aeruginosa adherence. Whereas
expression of iNOS is upregulated in inflammatory dis-
eases [106], expression of this enzyme is decreased in CF
[107,108], which may explain, at least partially, the
chronic airway infection. Although sites and techniques
for NO measurement are subjects at debate, patients with
CF have lower NO levels, certainly in parallel with low
expression of iNOS, but present high levels of peroxyni-
trite, nitrite and nitrates [109-114]. A possible explana-
tion has been proposed by Jones et al. [115], suggesting
the formation of nitrates and other NO metabolites by
reaction with superoxide anion, and then NO levels are
reduced. In addition, there is increasing evidence that
decreased NO formation contributes to airway obstruc-
tion in CF [111,116-118]. Interestingly, low NO levels are
correlated to both pancreatic insufficiency and chronic
Pseudomnas aeruginosa infection, suggesting that airway
NO could be associated with genotype and could be con-
sidered a risk factor for infection [111]. S-Nitrosothiols,
NO adducts that can mediate several effects of NO, are
also decreased in CF airways [119]. Thus, treatment with
S-nitrosothiols is able to increase expression, maturation
and function of both wild-type and mutated CFTR [120].
Moreover, low levels of S-nitrosoglutathione, a physiolog-
ical NO donor that acts as an innate-immune mediator,
Reactive oxygen species (ROS) affect DNA integrity, CFTR  function and can participate in the noxious cycle of inflamma- tion in CF cells Figure 3
Reactive oxygen species (ROS) affect DNA integrity, 
CFTR function and can participate in the noxious 
cycle of inflammation in CF cells.Respiratory Research 2009, 10:23 http://respiratory-research.com/content/10/1/23
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can enhance the deleterious effects of Pseudomonas aerugi-
nosa by affecting its metabolism [118]. Furthermore, treat-
ment of CF homozygote ΔF508 mice with LPS has no
effect on NO production, suggesting that decreased
expression of iNOS could contribute to chronic infection
of the airways [119].
CFTR and ceramides
Ceramides are sphingolipids, located in vesicles and cell
intermembranes. They are generated by hydrolysis of
sphingomyelin by acid sphingomyelinase (ASM) or by de
novo synthesis by ceramide synthase. They are degraded
by ceramidase to form fatty acid and sphingosin. Cera-
mides play crucial rules in signaling pathways. Recent
data suggest that ceramides may be involved in the patho-
genesis of CF. For instance, infection through Pseudomonas
aeruginosa favors interaction with rafts and activates ASM,
the latter translocates from intracellular vesicles to the
extracellular leaflet of the cell plasma membrane and gen-
erates ceramides. Then, ceramides induce rafts fusion to
form membrane platforms with receptors and molecule
clusters, like CD95 and CFTR, initiating signalization
[121], leading to cell death [48], regulation of NF-κB
pathway [122], and expression of pro-inflammatory
cytokines (Figure 1). Therefore, ceramides may represent
an important target for understanding and treating CF.
Like for apoptosis, levels of ceramides in CF cells are a
matter of debate. Vilela et al. [48] have shown a decreased
ceramide production in CFTRΔF508 lung epithelial cells
after treatment with TNF-α. For these authors, low levels
of ceramide production is due to high GSH levels that
inhibit ASM. This results in an exaggerated inflammation
due to absence of NF-κB inhibition by ceramides.
Recently, Teichgräber and colleagues [122] observed a
ceramide accumulation, age-dependent, in ciliated respi-
ratory, nasal epithelial cells, submucosal glands, and mac-
rophages from CFTR-deficient mice. In addition,
accumulation of ceramides, probably through an imbal-
ance between generation and degradation, is associated
with constitutive pulmonary inflammation and epithelial
cell death. Most interestingly, pharmacological inhibition
of ASM, in CFTR-deficient mice concomitantly normalizes
ceramide production and decreases pathological parame-
ters [122]. Altogether, these results and those of Vilela et
al. [48] demonstrate a modification of ceramide homeos-
tasis in CF associated with an exaggerated inflammatory
response to various stress inducers.
Conclusion and Perspectives
Intrinsic inflammation in CF, in the absence of patho-
gens, has multiple origins that make it difficult to resolve.
In addition, contradictory data on apoptosis in CF high-
light the need of further studies in order to explore the sta-
tus of programmed cell death in this pathology. As
detailed above, whether ER stress remains sustained, as
this occurs with CFTRΔF508 retention, cells initiate pro-
grammed death, and this could explain the activation of
NF-κB-associated pathways and inflammation observed
in CF. Although gene therapy may symbolize a real solu-
tion for the disease, the enthusiasm has been rapidly tem-
pered in view of the difficulties associated with the use of
viral and non-viral vectors, as well as the complexity of the
pathways controlling CFTR function. In this line, carrier
proteins delivering pharmacological chaperones may be
considered good candidates to new therapies leading to
correction of mutated CFTR [123]. However, very recently,
several pathways, up to date not linked to CFTR defi-
ciency, have been proposed to modulate inflammatory
response in CF and may represent new therapeutic
approaches.
Among these pathways, the peroxisome proliferator-acti-
vated receptor-γ (PPARγ) may be considered because of its
ability to participate in the transcription of various genes
involved in the regulation of the inflammatory response
[124]. In this respect, it has been recently described that
up-regulation of tissue transglutaminase may account for
the reduction of PPARγ expression in CFTR-defective cell
lines, and in this way, tissue transglutaminase inhibition
could regulate inflammation in CF cells [125]. In addi-
tion, these authors have shown that increase of intracellu-
lar calcium and excess of oxidative stress modulate tissue
transglutaminase activity, reinforcing the notion that both
calcium and ROS are implicated in the inflammatory
response in CF. In the same way, Perez et al. [126] have
shown that PPARγ agonists reduce cytokine secretion in
vitro and airway inflammation in response to Pseudomonas
aeroginosa in CF mice.
Natural products, mainly from vegetables, may also repre-
sent potential therapy in CF. In particular, flavonoids and
other bioactive compounds, with a large spectrum of bio-
logical effects such as anti-oxidant potential, could affect
different stages of CF pathogenesis. For instance, several
plant extracts have been found able to decrease secretion
of inflammatory cytokines from CF cells [127]. Others
correct defective electrolyte transport in CF airways acting
in parallel on second messengers and channel activities
[128]. Curcumin has also been described as a corrector of
the CFTR defect by eliciting increased CFTR traffic towards
the plasma membrane [129].
Nevertheless, until gene therapy is completely successful,
inflammation, in addition to elimination of infection
mucus, remains the main target in the treatment of CF. To
improve the effects of the different therapies, a better
knowledge of the intracellular and molecular mecha-
nisms involved in the regulation of CFTR traffic and func-
tion seems essential for correction of mutated CFTR at
different stages of impaired functions.Respiratory Research 2009, 10:23 http://respiratory-research.com/content/10/1/23
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